Nanostring Technologies Inc (NSTG) 12.25

New Post Public Reply Private Reply Replies (0) Message Board

Apr 23, 2015 at 1:11 AM

Nanostring Technologies Inc (NSTG) 12.25 $NSTG

NanoString Technologies to Release First Quarter 2015 Financial Results and Host Conference Call on Wednesday, May 6, 2015
GlobeNewswire - Wed Apr 22, 3:01PM CDT
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release first quarter 2015 financial results after the close of trading on Wednesday, May 6, 2015. Company management will host a conference call beginning at 4:30pm ET to discuss those results and to provide a business update.
NSTG: 12.25 (-0.02)

NanoString Technologies Empowers Cancer Researchers With Three Innovative New Products for the nCounter Analysis System
GlobeNewswire - Thu Apr 16, 4:00PM CDT
Introduction of RNA

rotein Profiling Panel Focused on Immuno-Oncology Addresses the Next Generation of Tumor Profiling
NSTG: 12.25 (-0.02)

NanoString Technologies and MD Anderson to Collaborate on Development of Multi-Omic Assays Simultaneously Profiling Gene and Protein Expression
GlobeNewswire - Wed Apr 01, 6:00AM CDT
The University of Texas MD Anderson Cancer Center and NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced a multi-year collaboration to accelerate the development and adoption of a revolutionary new type of assay based on NanoString's nCounter Analysis System. The collaboration will involve the development of "multi-omic" assays, which simultaneously profile both gene and protein expression, with a primary focus on identifying important biomarkers in the burgeoning field of immuno-oncology as well as extending programs for targeting therapeutics.
NSTG: 12.25 (-0.02)

NanoString Technologies' Prosigna Breast Cancer Assay Included in German Breast Cancer Treatment Guidelines
GlobeNewswire - Wed Mar 18, 2:00AM CDT
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that its Prosigna(R) Breast Cancer Assay is now acknowledged within the treatment guidelines of the German Association of Gynecological Oncology (AGO). In addition, under a recent decision by the German Joint Federal Committee (G-BA), qualifying German breast cancer patients with statutory government insurance will be eligible for coverage for gene expression testing, such as Prosigna, to inform therapy decisions beginning April 1, 2015.
NSTG: 12.25 (-0.02)

NanoString Technologies (NSTG): Moving Average Crossover Alert - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 7:35AM CDT
NanoString Technologies (NSTG): Moving Average Crossover Alert
NSTG: 12.25 (-0.02)

NanoString Technologies Appoints Robert Hershberg, M.D., Ph.D. to Its Board of Directors
GlobeNewswire - Tue Mar 03, 7:05AM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that Robert Hershberg, M.D., Ph.D. has been appointed to its Board of Directors, effective March 2, 2015. The Board now consists of six members.
NSTG: 12.25 (-0.02), CELGZ: 2.87 (+0.04)

NanoString Technologies' (NSTG) CEO Brad Gray on Q4 2014 Results -- Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 24, 10:10PM CST

NSTG: 12.25 (-0.02)

NanoString EPS in-line, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 3:14PM CST

NSTG: 12.25 (-0.02)

Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 4:35PM CST

AMRS: 2.61 (unch), AWAY: 32.27 (+0.76), HWAY: 18.99 (-0.08), FLTX: 47.90 (+0.56), HLS: 46.35 (+0.48), RRC: 60.72 (+0.93), DY: 48.32 (+0.41), MATX: 42.01 (+0.77), NYMT: 7.87 (+0.05), NSTG: 12.25 (-0.02), PZZA: 61.35 (-0.57), SGY: 16.54 (-0.83), HEP: 33.25 (+0.13), ARC: 9.05 (-0.01), BGFV: 12.36 (+0.16), RJET: 13.09 (-0.07), RLYP: 35.39 (-0.54), SAM: 261.44 (-2.60), DWA: 26.12 (-0.26), NKTR: 10.90 (+0.16), FSLR: 63.88 (+0.77), NFX: 37.77 (+0.79), KONA: 26.24 (-0.63), BBRG: 14.98 (-0.02), HEI: 59.00 (-0.34), CLR: 51.80 (+0.98), ACAS: 15.18 (+0.04), RUBI: 17.36 (-0.23), HURN: 66.98 (-0.18), GB: 54.53 (-0.02), BNFT: 36.87 (-0.20), AWK: 54.26 (+0.38), NUVA: 43.38 (+0.10), BOOM: 13.03 (-0.02), CENX: 13.28 (+0.17), GNMK: 10.51 (-0.22), QEP: 22.17 (-0.01), FMI: 48.71 (-0.96), KRA: 20.05 (+0.37), DPM: 39.93 (+0.29), JAZZ: 186.13 (-0.41), INFI: 14.71 (-0.28), EPR: 59.11 (-0.21), EXEL: 3.12 (+0.05), CBI: 49.62 (-1.62), NDSN: 80.39 (+0.80), ORA: 37.84 (+0.22), CPRT: 37.19 (-0.16), SM: 55.21 (+1.23), HPQ: 33.51 (+0.30), NLY: 10.27 (+0.02), LC: 19.01 (-0.34), DYN: 33.28 (+0.24), CLGX: 35.61 (-0.03), SLCA: 36.94 (+0.70), EIX: 60.01 (-0.49), MMSI: 18.79 (+0.45)

Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 1.06 (-0.01), AMRN: 2.34 (-0.05), HWAY: 18.99 (-0.08), HLS: 46.35 (+0.48), CYBX: 63.59 (+0.27), ESRX: 86.12 (+0.02), ECYT: 6.37 (unch), DXCM: 69.28 (-1.05), NSTG: 12.25 (-0.02), SRPT: 13.52 (+0.04), HZNP: 30.96 (+0.10), MDXG: 10.21 (-0.17), DEPO: 27.14 (+0.65), ANIK: 38.68 (+0.05), NKTR: 10.90 (+0.16), KERX: 11.52 (-0.15), ALIM: 4.92 (-0.09), EPZM: 19.45 (+0.45), AEGR: 25.65 (+0.06), MDRX: 12.30 (+0.12), ELGX: 17.07 (+0.15), NUVA: 43.38 (+0.10), HPTX: 45.96 (-0.18), GNMK: 10.51 (-0.22), MDVN: 128.88 (+0.29), HBIO: 6.06 (-0.29), ACAD: 38.55 (-0.20), ST: 58.27 (+0.21), RPTP: 10.56 (-0.17), FMI: 48.71 (-0.96), GMED: 25.09 (-0.16), JAZZ: 186.13 (-0.41), PTCT: 70.98 (unch), INFI: 14.71 (-0.28), ARNA: 4.47 (+0.01), EXEL: 3.12 (+0.05), NEO: 4.84 (-0.03), EXAS: 22.28 (+0.24), ALKS: 62.60 (-0.24), HTWR: 77.60 (-2.35), MNKD: 4.90 (-0.09), IPXL: 49.58 (-0.40), SQNM: 4.47 (+0.08), HALO: 16.03 (+0.15), ISIS: 66.26 (-0.03), CLVS: 85.04 (-1.36), BIO: 136.64 (+0.02), BIOS: 5.23 (+0.04), PCRX: 83.61 (-0.41)

NanoString Technologies to Present at the Cowen 35th Annual Health Care Conference
GlobeNewswire - Wed Feb 18, 3:35PM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that its management is scheduled to present at the Cowen and Company 35 Annual Health Care Conference in Boston.
NSTG: 12.25 (-0.02)

Be on Top of the Latest Happenings: Special Research on La Jolla, Lpath, Macrocure, Momenta, and NanoString
PR Newswire - Tue Feb 17, 8:05AM CST
Editor Note: For more information about this release, please scroll to bottom.
NSTG: 12.25 (-0.02), LJPC: 23.04 (+1.22), MCUR: 9.90 (+0.09), MNTA: 18.62 (+0.56), LPTN: 2.26 (unch)

NanoString Technologies to Release Fourth Quarter 2014 Financial Results and Host Conference Call on Tuesday, February 24, 2015
GlobeNewswire - Tue Feb 10, 3:07PM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release fourth quarter 2014 financial results after the close of trading on Tuesday, February 24, 2015. Company management will host a conference call beginning at 4:30pm ET to discuss those results and to provide a business update.
NSTG: 12.25 (-0.02)

Labcyte Names Chris Grimley as Vice President of Marketing
Business Wire - Mon Feb 09, 7:08AM CST
Labcyte Inc., the company revolutionizing life science research with the Echo(R) liquid handler, today announced the appointment of Chris Grimley as Vice President of Marketing. Mr. Grimley will be responsible for leading the global marketing and product management teams, driving demand for products and services, and growing sales of the Echo liquid handler in emerging application areas such as in synthetic biology, next generation sequencing and personalized medicine.
NSTG: 12.25 (-0.02), A: 42.71 (-0.18)

NanoString Technologies to Present at 2015 Leerink Global Healthcare Conference
GlobeNewswire - Wed Jan 28, 7:09AM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that its management is scheduled to present at the 2015 Leerink Global Healthcare Conference in New York.
NSTG: 12.25 (-0.02)

NanoString Technologies Provides Update on 2014 Operational and Preliminary Financial Results
GlobeNewswire - Thu Jan 08, 3:06PM CST
- Expected Full Year 2014 Revenue Growth of 50% to 53% Year over Year -
NSTG: 12.25 (-0.02)

NanoString Technologies to Present at J.P. Morgan 33rd Annual Healthcare Conference
GlobeNewswire - Mon Dec 22, 7:00AM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that its management is scheduled to present at the J.P. Morgan 33 Annual Healthcare Conference in San Francisco.
NSTG: 12.25 (-0.02), JPM: 62.94 (+0.63)

NanoString Technologies Highlights Important Results from Prosigna Decision Impact Study Presented at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium
Business Wire - Mon Dec 15, 3:05PM CST
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the results of the first Prosigna(R) Assay decision impact study presented at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) showed that the use of the test significantly changed oncologists' treatment recommendations. Conducted in collaboration with Grupo Espanol de Investigacion del Cancer de Mama (GEICAM), a Spanish breast cancer research group, this prospective study of the Prosigna Assay and its impact on the treatment of women with Estrogen Receptor-Positive (ER+), HER2-negative, node-negative breast cancer showed that the use of the test informed the oncologists' recommendation whether or not to treat with adjuvant chemotherapy in addition to adjuvant endocrine therapy.
NSTG: 12.25 (-0.02)

NanoString Technologies Updates Prosigna FDA Labeling to Provide Greater Insight into Probability of Breast Cancer Recurrence Between Year 5 and 10 After Diagnosis
Business Wire - Mon Dec 08, 3:40PM CST
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the U.S. Food and Drug Administration (FDA) has cleared a labeling update for the Prosigna(R) Breast Cancer Gene Signature Assay. The labeling update is derived from the analysis of data by researchers from the Austrian Breast and Colorectal Cancer Study Group Trial 8 (ABCSG-, who previously reported that the Prosigna Assay accurately assessed the probability of distant recurrence in postmenopausal women with Estrogen Receptor-Positive (ER+) early-stage breast cancer.
NSTG: 12.25 (-0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ford Foundation Welcomes Gender Justice Leader Fatima Goss Graves

A Fresh Addition to Ford's Trustees Fatima Goss Graves steps into big shoes at the Ford Foundation as she gets appointed to its Board of Trustees. No small potatoes, this move suggests the Foundation's commitment to driving significant gender justice and advocacy. Add her name next to serious change-makers, folks, because Ms. Goss Graves is a heavyweight in the nonprofit...

Coastal Financial Faces Lawsuit Over Fraud Allegations

Coastal Financial Corporation, riding high on NASDAQ as CCB, now finds itself in the middle of a storm. Schall, Brown & Schwartz LLP, a firm known for its shareholder rights litigation, has thrown the gauntlet with a class action lawsuit against Coastal for suspected securities violations. We're talking about potential fibs under Section 10(b) and 20(a) of the Securities...

Moore Law Urges Millrose Investors: Join the Action

Is Millrose Playing a Risky Game? When I caught wind of this latest debacle with Millrose Properties, Inc. (NYSE: MRP), my gut reaction was a mix of curiosity and skepticism. Hunterbrook Media's report just blasted across the headlines, digging up some dirt on Millrose's recent financial maneuvers. Apparently, these cats have been busy buying homes to the tune of $200...

Ruth E. Carter Returns Home with Celebrated Exhibition

Ruth E. Carter’s Triumphant Return When a titan of the costume design world circles back to their roots, you know it’s bound to be something special. Ruth E. Carter, who has swapped needles and threads for Oscars (twice, mind you), is making a return to Hampton University, paying homage to the very soil that sowed her artistic seeds. Ain't that a capstone of a career...

PrePass Intelligence: A Game-Changer for Fleets

Picture this: you're at the wheel of a beastly 18-wheeler, barreling down the highway and skipping weigh stations thanks to PrePass. But here’s where the real magic kicks in. PrePass Intelligence just rolled out, aiming to squeeze every last drop of value from bypass and toll data. That's cold hard cash for fleet operators who can finally make sense of these fleeting...

Ball Corp's Leadership Shuffle Aims for Strategic Gains

Leadership Changes in the Midst of Market Challenges You don't need a crystal ball to see that leadership changes can signal either turmoil or opportunity. Ball Corporation, a titan in the realm of aluminum packaging, is experiencing a shake-up at the top of its beverage packaging business units. With Carey Causey stepping into the role for North and Central America, and...

Art Print Paper: Finding the Perfect Match for Masterpieces

You ever stand in a gallery and notice how some art just lights up the room while others barely get a second glance? Well, a lot of that magic starts with an unsung hero—paper choice. I came across this bit from HelloNation diving into what makes paper selection a cornerstone for fine art prints. Now, I ain't an artist, but even a bruiser trader like me can see the...

QFIN Faces Class Action: Investors' Role Explored

Cracks in the Facade: QFIN's Legal Mess You're cruising down the usual market lanes when—bam!—news breaks that Qfin Holdings, Inc. (NASDAQ: QFIN) finds itself hip-deep in a class action lawsuit. Seems like our pals at Schall, Brown & Schwartz LLP have thrown the gauntlet down, with claims of some serious smoke and mirrors during the March to August stretch of 2026....

Spooky Suds: House of Horror Meets El Car Wash

A Haunted Wash Awaits Miami Drivers Picture this: you're cruising down West Flagler on a regular Wednesday evening, but tonight, you're not just rolling in for a rinse. Nope, this Wednesday night, the wash tunnel at El Car Wash gets downright spooky. It's getting a haunted house makeover with scare actors from the House of Horror. When a Car Wash Becomes a Haunted...

OppFi Readies Q3 Earnings; Investors Eye Financials

What's Unfolding at OppFi? Mark your calendars, folks. October 28th is the day OppFi (NYSE: OPFI) pulls the curtain back on its third-quarter 2026 earnings. For the uninitiated, we're talking about a tech-driven finance platform that's been making waves by providing financial solutions for everyday Americans. And you bet we're all ears for what those numbers say. Details...